Follow Us TR

News Details

Novus Therapeutics Announces Topline Results of Phase 2a Clinical Trial of OP0201 in Acute Otitis Media

About Novus Therapeutics, Inc.
  • NASDAQ: $NVUS
  • Notified: $1.27
  • 08:32 EDT

Price Chart